From: Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
CAR-T antigen | Clinical study | Disease |
---|---|---|
CD19 | Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma | B-cell lymphoma; B-ALL |
BAFF-R | Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions | B- ALL; B-NHL |
CD20 | Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma | R/R DLBCL |
CD22 | CD19/CD22 Dual-Targeted CAR-T Therapy Active in Relapsed/Refractory DLBCL | R/R DLBCL |
CD79b | Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas | B-cell lymphoma |
CD37 | Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma | R/R B-NHL |
PD-1 | CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma | PD-L1 Positive B-Cell Lymphoma |
Igκ | T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells | Low-grade NHL; B-CLL |